🇺🇸 FDA

Company profile · Sponsor

Cardiff

Cardiff Oncology

CRDF · NYSE biotech SAN DIEGO, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Cardiff (CRDF) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CRDF
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001213037

Pipeline (24)

Search pipeline →

  1. Arm A Mylotarg plus DA Versus CPX-351

    Cardiff

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  2. Azithromycin

    Cardiff

    Bronchopulmonary Dysplasia

    phase 3 small molecule terminated

    1 trial

  3. CISPLATIN, CARBOPLATIN

    Cardiff

    Human papillomavirus (HPV)-positive oropharyngeal cancer

    phase 3 small molecule active

    1 trial

  4. Intravenous Methylprednisolone

    Cardiff

    Myelitis, Transverse

    phase 3 small molecule terminated

    1 trial

  5. Mycophenolate Mofetil

    Cardiff

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  6. Oral triiodothyronine

    Cardiff

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  7. Tetronine

    Cardiff

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  8. mesalazine (Asacol®)

    Cardiff

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  9. AZD5363

    Cardiff

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial

  10. Aspirin

    Cardiff

    Venous Leg Ulcer

    phase 2 small molecule terminated

    1 trial

  11. Colonoscopy with enhanced dye

    Cardiff

    Colorectal Cancer

    phase 2 other completed

    1 trial

  12. FOLFIRI regimen

    Cardiff

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  13. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff

    Blood cancer

    phase 2 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Cardiff

    Anal cancer

    phase 2 small molecule active

    1 trial

  15. LAB4

    Cardiff

    Graves' Disease

    phase 2 mab active

    1 trial

  16. Leucovorin

    Cardiff

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  17. Low Molecular Weight Heparin (LMWH)

    Cardiff

    Cancer

    phase 2 small molecule terminated

    1 trial

  18. Motivational Interviewing

    Cardiff

    Diabetes Mellitus

    phase 2 other terminated

    1 trial

  19. Onvansertib

    Cardiff

    Breast Cancer

    phase 2 small molecule active

    1 trial

  20. Onvansertib

    Cardiff

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  21. Onvansertib

    Cardiff

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  22. Onvansertib

    Cardiff

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  23. Onvansertib

    Cardiff

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  24. Onvansertib

    Cardiff

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12383540

    Compounds that modulates AMPA receptor function

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12318418

    Modified adenoviruses

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12053513

    Cancer-specific T-cell receptors

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11850264

    Gamma delta T-cell receptor and its ligand

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11725039

    α/β t-cell receptor and methods of using it

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Cardiff?

Cardiff (CRDF) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Cardiff sponsor?

We track 24 ClinicalTrials.gov-linked programs for Cardiff, including Arm A Mylotarg plus DA Versus CPX-351 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Cardiff company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.